“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

29 November 2019
Pharma

Visiongain has launched a new pharma report ‘’Nucleic Acid Isolation and Purification Market Report 2020-2030’’ by Product (Kits, Reagents, Instruments), Method (Column-Based Isolation and Purification, Magnetic Bead-Based Isolation and Purification, Reagent-Based Isolation and Purification, Other Methods), Type (Plasmid Dna Isolation and Purification, Genomic Dna Isolation and Purification, Microrna Isolation and Purification, Circulating Nucleic Acid Isolation and Purification, Total Rna Isolation and Purification, Messenger Rna Isolation and Purification, PCR Cleanup, Other Types), Application (Agriculture and Animal Research, Diagnostics, Drug Discovery & Development, Precision Medicine, Other Applications), End Users (Academic and Government Research Institutes, CRO’s, Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Other End Users), and Geography.

The global nucleic acid isolation and purification market is anticipated to grow at a lucrative CAGR of 9.8% and anticipated to reach USD 8.16 Billion by 2030.

Nucleic acid separation and purification is one of modern science and technology's most complex and critical accomplishments. With the decreasing cost of genomic sequencing and the use of high-performance platforms and software, the market is anticipated to witness lucrative growth over the forecast period from 2020 to 2030.

Globally, an increase in the prevalence of genetic disorders, cancer, and infectious diseases has also played a major role in the development of the market. Therefore, demand for genetically modified crops and fruits for consumption and genetically modified organisms for research studies has increased, further demand for the isolation and purification of nucleic acid has increased.

The nucleic acid isolation and purification market growth is also fueled by growing private and public collaborations in the life science and biotechnology sectors, growing adoption of sequencing technologies for clinical diagnostics, increasing genomic and enzymology-based research, and rising R&D innovation in molecular biology and precision medicines.

In contrast, the use of nucleic acids has inspired in blood screening, genetic disorders, infectious disease identification, oncology, and precision medicine. This is due to the emergence of advanced technologies that are user-friendly & helpful in evaluating the selection of specimens & obtaining accurate results.

The nucleic acid isolation and purification market is highly fragmented and comprise heavy competition form the well-established companies. However, some factors are challenging market growth which includes lack of automation and lack of skilled professionals, high instrument costs, and low penetration in emerging countries. As a result, the industry has paved the way for the growth in this space for new players with disruptive technologies. Also, technologies of next-generation sequencing (NGS) and the easy availability of genomic data provide players with heavy opportunities.

Pharmaceutical and biotech companies are increasing demand due to increased automation in the application of nucleic acid isolation & purification for clinical diagnosis & genetic testing. The growth and advancement of nucleic acid isolation and purification have been driven by rapidly growing biotechnological applications in various industries such as food processing, farming, recycling, and waste management, energy and climate.

North America holds the majority of market share owing to factors such as the presence of a large number of software providers, improved patient knowledge, advanced healthcare facilities, and rapid acceptance of advanced technologies such as NGS (next-generation sequencing). The North American nucleic acid market is also strongly supported by support from government research and development.

Asia Pacific nucleic acid market is anticipated to grow with the highest CAGR over the forecast period from 2020 to 2030 owing to growing healthcare expenditure, growing economies across India, China and Japan, and increased government investment in research and development projects. Another major factor that is fueling the nucleic acid isolation and purification market across the Asia Pacific region is a growing demand for quality healthcare for a growing patient pool.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the global nucleic acid isolation and purification market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the nucleic acid isolation and purification market.

The comprehensive market report features companies such as Agilent Technologies, Bio-Rad Laboratories, Danaher Corporation, F. Hoffman-La Roche Ltd., Ge Healthcare, Illumina, Merk KGaA, New England Biolabs, Norgen Biotek Corp., Promega Corporation, Qiagen N.V., Takara Bio, Inc., Thermo Fisher Scientific, Thermo Fisher Scientific, BioTek Instruments Inc., BioVision Inc. among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

Read

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

Read

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

Read

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever